<DOC>
	<DOCNO>NCT01010893</DOCNO>
	<brief_summary>To determine tolerability immunogenicity FLUVAL P monovalent influenza vaccine adult elderly people , objective verify efficacy tolerability study drug .</brief_summary>
	<brief_title>Tolerability Immunogenicity Fluval P Monovalent Influenza Vaccine</brief_title>
	<detailed_description>Primary Objective : To assess tolerability/safety ( incidence adverse event ) study drug . To assess efficacy ( immunogenicity ) study drug serology test blood sample take Day 21‑28 immunization group age group . Secondary Objectives : To assess long-term safety study drug 50-60 day immunization . To determine tolerability simultaneous administration FLUVAL P monovalent pandemic influenza vaccine FLUVAL AB trivalent seasonal influenza vaccine case adult elderly people . To assess efficacy study drug optional epidemiological follow-up participant end influenza season . To assess immunogenicity study drug optional cross-reactive immunity test perform non-homologous influenza A B virus strain .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Adults age 18 60 year , elderly people age 60 year , sex , full contractual capacity ; Are good health ( determine vital sign exist medical condition ) stable medical condition . Subjects exclude know adequately treat clinically significant organ systemic disease ( e.g . asthma diabetes ) , , opinion investigator , significance disease compromise subject 's participation study ; Femal volunteer childbearing potential negative result urine pregnancy test prior vaccination agree use acceptable contraception method abstinence throughout trial become pregnant duration study . Capable understand comply study protocol requirement ; The volunteer provide write informed consent prior initiation study procedure ; Absence existence exclusion criterion . Pregnancy breast feed positive urine pregnancy test baseline prior vaccination ; Known allergy egg component vaccine ( particular mercury ) ; History GuillainBarré syndrome ; Active neoplasm ; Immunosuppressive therapy precede 36 month ; Concomitant corticosteroid therapy , include highdose inhaled corticosteroid ; Immunoglobulin ( similar blood product ) therapy within 3 month prior vaccination ; Documented HIV , HBV HCV infection ; Chronic illness , opinion investigator , may interfere evaluation immunoresponse ; Acute febrile respiratory illness within one week prior vaccination ; Vaccine therapy within 4 week prior vaccination ; Influenza vaccination within 6 month prior vaccination ; Experimental drug therapy within 1 month prior vaccination ; Past current psychiatric disease volunteer upon judgement investigator may effect objective decisionmaking volunteer ; Alcohol drug abuse participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pandemic</keyword>
	<keyword>prevention</keyword>
	<keyword>influenza</keyword>
	<keyword>infection</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>vaccine</keyword>
	<keyword>influenza human</keyword>
</DOC>